

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Overview

The [Direxion Daily Pharmaceutical & Medical Bull 3X Shares](#) seeks daily investment results, before fees and expenses, of 300% of the performance of the S&P Pharmaceuticals Select Industry Index. **There is no guarantee the fund will meet its stated investment objective.**

This leveraged ETF seeks a return that is 300% the return of its benchmark index **for a single day. The fund should not be expected to provide three times the return of the benchmark's cumulative return for periods greater than a day.**

Target Index

The S&P Pharmaceuticals Select Industry Index (SPSIPHTR) is a modified equal-weighted index that is designed to measure performance of the stocks comprising the S&P Total Market Index that are classified in the Global Industry Classification Standard (GICS) pharmaceuticals sub-industry. **One cannot directly invest in an index.**

Investing in a Direxion Shares ETF may be more volatile than investing in broadly diversified funds. The use of leverage by a Fund increases the risk to the Fund. The Direxion Shares ETFs are not suitable for all investors and should be utilized only by sophisticated investors who understand leverage risk, consequences of seeking daily leveraged, or daily inverse leveraged, investment results and intend to actively monitor and manage their investment.

PILL

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Fund Facts

| | |
|---------------------------|------------|
| Fund Symbol | PILL |
| Intraday Indicative Value | PILL.IV |
| Bloomberg Index Symbol | SPSIPHTR |
| CUSIP | 25460E646 |
| Daily Target | 300% |
| Gross Expense Ratio | 1.13% |
| Net Expense Ratio* | 1.00% |
| Inception Date | 11/15/2017 |

**The Net Expense Ratio includes management fees, other operating expenses and Acquired Fund Fees and Expenses. If Acquired Fund Fees and Expenses were excluded, the Net Expense Ratio would be 0.95%. The Fund's adviser, Rafferty Asset Management, LLC ("Rafferty") has entered into an Operating Expense Limitation Agreement with the Fund. Under the Operating Expense Limitation Agreement, Rafferty has contractually agreed to waive all or a portion of its management fee and/or reimburse the Fund for Other Expenses through September 1, 2024, to the extent that the Fund's Total Annual Fund Operating Expenses exceed 0.95% of the Fund's average daily net assets (excluding, as applicable, among other expenses, taxes, swap financing and related costs, acquired fund fees and expenses, dividends or interest on short positions, other interest expenses, brokerage commissions and extraordinary expenses). If these expenses were included, the expense ratio would be higher.*

Index Top Ten Holdings %

| | |
|----------------------|------|
| Perrigo | 4.69 |
| Jazz Pharmaceuticals | 4.55 |
| Organon & Co | 4.48 |
| Viatis | 4.48 |
| Axsome Thera | 4.47 |
| Merck & Co | 4.42 |
| Lilly | 4.39 |
| Catalent | 4.37 |
| Johnson & Johnson | 4.36 |
| Pfizer | 4.30 |

Index Sector Weightings %

| | |
|-----------------|--------|
| Pharmaceuticals | 100.00 |
|-----------------|--------|

Index data as of 12/31/2022. Index weightings and holdings are subject to change.

Performance (As of 12/31/2022)

| | | 1M % | 3M % | YTD % | 1Y % | 3Y % | 5Y % | S/I of the fund % | Inception Date |
|----------|--------------|--------|------|--------|--------|--------|--------|-------------------|----------------|
| PILL | NAV | -13.77 | 1.49 | -43.13 | -43.13 | -29.11 | -19.48 | -17.81 | 11/15/17 |
| | Market Close | -13.51 | 1.39 | -43.15 | -43.15 | -29.04 | -19.60 | -17.81 | |
| SPSIPHTR | | -4.21 | 2.46 | -10.22 | -10.22 | -2.68 | -0.29 | 0.82 | |

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate. An investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance quoted. Returns for performance under one year are cumulative, not annualized. For the most recent month-end performance please visit the funds website at direxion.com.

Short-term performance, in particular, is not a good indication of the fund's future performance, and an investment should not be made based solely on returns. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes. For additional information, see the fund's prospectus.

FOR INFORMATION: 866-476-7523 | INFO@DIREXION.COM | DIREXION.COM

An investor should carefully consider the Fund's investment objective, risks, charges, and expenses before investing. The Fund's prospectus and summary prospectus contain this and other information about the Direxion Shares. To obtain the Fund's prospectus and summary prospectus call 866-476-7523 or visit our website at direxion.com. The Fund's prospectus and summary prospectus should be read carefully before investing.

CUSIP Identifiers have been provided by CUSIP Global Services, managed on behalf of the American Bankers Association by Standard and Poor's Financial Services, LLC, and are not for use or dissemination in any manner that would serve as a substitute for a CUSIP service. The CUSIP Database, ©2011 American Bankers Association. "CUSIP" is a registered trademark of the American Bankers Association.

Shares of the Direxion Shares are bought and sold at market price (not NAV) and are not individually redeemed from a Fund. Market Price returns are based upon the midpoint of the bid/ask spread at 4:00 pm EST (when NAV is normally calculated) and do not represent the returns you would receive if you traded shares at other times. Brokerage commissions will reduce returns. Fund returns assume that dividends and capital gains distributions have been reinvested in the Fund at NAV. Some performance results reflect expense reimbursements or recoupments and fee waivers in effect during certain periods shown. Absent these reimbursements or recoupments and fee waivers, results would have been less favorable.

The "S&P Pharmaceuticals Select Industry Index" is a product of S&P Dow Jones Indices LLC ("SPDJI"), and has been licensed for use by Rafferty. Standard & Poor's® and S&P® are registered trademarks of Standard & Poor's Financial Services LLC ("S&P"); Dow Jones® is a registered trademark of Dow Jones Trademark Holdings LLC ("Dow Jones"); and these trademarks have been licensed for use by SPDJI and sublicensed for certain purposes by Rafferty. Rafferty's ETFs are not sponsored, endorsed, sold or promoted by SPDJI, Dow Jones, S&P, or their respective affiliates and none of such parties make any representation regarding the advisability of investing in such product(s) nor do they have any liability for any errors, omissions, or interruptions of the S&P Pharmaceuticals Select Industry Index.

Direxion Shares Risks – An investment in the Fund involves risk, including the possible loss of principal. The Fund is non-diversified and includes risks associated with the Fund concentrating its investments in a particular industry, sector, or geographic region which can result in increased volatility. The use of derivatives such as futures contracts and swaps are subject to market risks that may cause their price to fluctuate over time. Risks of the Fund include Effects of Compounding and Market Volatility Risk, Leverage Risk, Market Risk, Counterparty Risk, Rebalancing Risk, Intra-Day Investment Risk, Daily Index Correlation Risk, Other Investment Companies (including ETFs) Risk, Cash Transaction Risk, Tax Risk, and risks specific to the securities of the Biotechnology Industry, Healthcare Sector and Pharmaceutical Industry. The profitability of pharmaceutical companies is highly dependent on the development, procurement and marketing of drugs and the development, protection and exploitation of intellectual property rights and other proprietary information. Please see the summary and full prospectuses for a more complete description of these and other risks of the Fund.